App Chem-Bio

App Chem-Bio, also known as Apege Biomedical, is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule drugs for "undruggable" targets. Headquartered in Suzhou, China, the company utilizes a proprietary platform that combines fragment-based drug discovery (FBDD) with advanced covalent chemistry to address challenging protein-protein interactions and mutations. Their primary therapeutic focus is oncology, with a pipeline featuring inhibitors for KRAS G12D, SOS1, and WRN. App Chem-Bio is led by a team of industry veterans with extensive experience in global pharmaceutical R&D. The company has successfully raised significant venture capital to advance its lead programs into clinical trials.